Diminished expression of the type II receptor for TGFβ (TGFβRII) in T lymphocytes from patients with Sezary syndrome is not due to mutations in the receptor's poly-A tract: Limitations of the standard RT-PCR in cDNA sequence analysis of homopolymeric base stretches

Archivum Immunologiae et Therapiae Experimentalis

Volumn 50, Issue 6, 2002, Pages 421-429

  Zhang, Qian ^a   Capocasale, Renold J ^a   Fox, Floyd E ^a   Bedian, Vahe ^a   Vonderheid, Eric C ^b   Rook, Alain ^a   Moore, Jonni S ^a   Nowell, Peter C ^a   Haines, Dale S ^b   Wasik, Mariusz A ^a  

^a University of PA Medical Center   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cutaneous T cell lymphoma; Poly A tract sequence analysis; Sezary syndrome; Type II receptor for TGF

Indexed keywords

COMPLEMENTARY DNA; DNA POLYMERASE; GENOMIC DNA; POLYADENYLIC ACID; RECEPTOR SUBTYPE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENE MUTATION; GENOME; HUMAN; HUMAN CELL; LYMPHOCYTE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEZARY SYNDROME; SINGLE STRAND CONFORMATION POLYMORPHISM; T CELL LYMPHOMA;

BASE SEQUENCE; DNA, COMPLEMENTARY; HUMANS; MUTATION; POLY A; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEZARY SYNDROME; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0036952174     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. BLOBE G. C., SCHIEMANN W. P. and LODISH H. F. (2000): Role of transforming growth factor β in human disease. N. Engl. J. Med., 342, 1350-1358.
2. CAPOCASALE R. J., LAMB R. J., VONDERHEID E. C., FOX F. E., ROOK A. H., NOWELL P. C. and MOORE J. S. (1995): Reduced surface expression of transforming growth factor β receptor type II in mitogen-activated T cells from Sezary patients. Proc. Natl. Acad. Sci. USA, 92, 5501-5505.
3. DERYNCK R., ZHANG Y. and FENG X.-H. (1998): Smads: transcriptional activators of TGF-β responses. Cell, 95, 737-740.
4. FALINI B. and MASON D. Y. (2002): Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood, 99, 409-426.
5. GARRIGUE-ANTAR L., MUNOZ-ANTONIA T., ANTONIA S. J., GESMONDE J., VELLUCCI V. F. and REISS M. (1995): Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells. Cancer Res., 55, 3982-3987.
6. HELDIN C.-H., MIYAZOMO K. and TEN DIJKE P. (1997): TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature, 390, 465-471.
7. IMAI Y., TSURUTANI N., ODA H., INOUE T. and ISHIKAWA T. (1998): Genetic instability and mutation of the TGF-β-receptor-II gene in ampullary carcinomas. Int. J. Cancer, 76, 407-411.
8. IZUMOTO S., ARITA N., OHNISHI T., HIRAGA S., TAKI T., TOMITA N., OHUE M. and HAYAKAWA T. (1997): Microsatellite instability and mutated type II transforming growth factor-β receptor gene in gliomas. Cancer Lett., 112, 251-256.
9. KADIN M. E., CAVAILLE-COLL M., GERTZ R., MASSAGUE J., CHEIFETZ S. and GEORGE D. (1994): Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc. Natl. Acad. Sci. USA, 91, 6002-6007.
10. KRETZSCHMAR M. and MASSAGUÉ J. (1998): SMADS: mediators and regulators of TGF-β signaling. Curr. Opin. Genet. Dev., 8, 103-111.
11. LIN H. Y., WANG X. F., NG-EATON E., WEINBERG R. A. and LODISH H. F. (1992): Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell, 68, 775-785 (published erratum appeared in Cell, 1992, 70, 1068)
12. MARKOWITZ S., WANG J., MYEROFF L., PARSONS R., LUZHE S., LUTTERBAUGH J., FAN R. S., ZBOROWSKA E., KINZLER K. W., VOGELSTEIN B., BRATTAIN M. and WILLSON J. K. V. (1995): Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science, 268, 1336-1338.
13. MIYAZAKI T., MARUYAMA M., YAMADA G., HATAKEYAMA M. and TANIGUSHI T. (1991): The integrity of the conserved "WS motif" common to IL-2 and other cytokine receptors is essential for ligand binding, and activation of the receptor. EMBO J., 10, 3191-3197.
14. NAKASHIMA K., YANAGISAWA M., ARAKAWA H., KIMURA N., HISATSUNE T., KAWABATA M., MIYAZONO K. and TAGA T. (1999): Synergistic signaling in fetal brain by STAT3-Smadl complex bridged by p300. Science, 284, 479-482.
15. SAMOWITZ W. S. and SLATTERY M. L. (1997): Transforming growth factor-β receptor type 2 cutations and microsatellite instability in sporadic colorectal adenomas and carcinomas. Am. J. Pathol., 151, 33-35.
16. SUN P., DONG P., DAI K., HANNON G. J. and BEACH D. (1998): p53-independent role of MDM2 in TGF-1 resistance. Science, 282, 2270-2272.
17. SUN Y., LIU X., NG-EATON E., LODISH H. F. and WEINBERG R. A. (1999): SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor β signaling. Proc. Natl. Acad. Sci. USA, 96, 12442-12447.
18. TAKENOSHITA S., HAGIWARA K., GEMMA A., NAGASHIMA M., RYBERG D., LINDSTEDT B. A., BENNETT W. P., HAUGEN A. and HARRIS C. C. (1997): Absence of mutations in the transforming growth factor-β type II receptor in sporadic lung cancers with microsatellite instability and rare H-rasl alleles. Carcinogenesis, 18, 1427-1429.
19. VINCENT F., NAGASHIMA M., TAKENOSHITA S., KHAN M. A., GEMMA A., HAGIWARA K., BENNETT W. P. (1997): Mutation analysis of the transforming growth factor-β type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-β. Oncogene, 15, 117-122.
20. VONDERHEID E. C., BERENGO M. G., BURG G., DUVIC M., HEALD P., LAROCHE L., OLSEN E., PITTELKOW M., RUSSEL-JONES R., TAKIGAWA M. and WILLEMZE R. (2002): Update on erythrodermic cutaneous T cell lymphoma: report of the International Society for Cutaneous Lymphomas. J. Am. Acad. Dermatol., 46, 95-106.
21. WATOWICH S. S., HILTON D. J. and LODISH H. F. (1994): Activation and inhibition of erythropoietin receptor function of receptor: role of receptor dimerization. Mol. Cell. Biol., 14, 3535-3549.
22. WILLEMZE R. (2002): Primary cutaneous lymphomas. Curr. Opin. Oncol., 12, 419-425.
23. Wu M. S., LEE C. W., SHUN C. T., WANG H. P., LEE W. J., SHEU J. C. and LIN J. T. (1998): Clinicopathological significance of altered loci of replication error and microsatellite instability-associated mutations in gastric cancer. Cancer Res., 58, 1494-1497.
24. YOSHIMURA A., ZIMMERS T., NEUMANN D., LONGMORE G., YOSHIMURA Y. and LODISH H. F. (1992): Mutations in the Trp-Ser-X-Trp-Ser motif of the erythropoietin receptor abolish processing, ligand binding, and activation of the receptor. J. Biol. Chem., 267, 11619-11625.
25. ZHANG Q., RAGHUNATH P. N., VONDERHERD E., ØDUM N. and WASIK M. A. (2000): Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T cell lymphoma cells results from methylation of the SHP-1 promoter. Am. J. Pathol., 157, 1137-1146.
26. ZHANG Q., RAGHUNATH P. N., XUE L., MAJEWSKI M., CARPENTIERI D. F., ODUM N., MORRIS S., SKORSKI T. and WASIK M. A. (2002): Multilevel dysregulation of STAT3 activation in ALK+ T/null-cell lymphoma. J. Immunol., 168, 466-474.